(Q34120859)

31 July 2017

Emerging oral therapies in multiple sclerosis (English)

1 reference

31 July 2017

0 references

Devon Conway

1

1 reference

PubMed ID

20549393

31 July 2017

Jeffrey A Cohen

series ordinal

2

1 reference

31 July 2017

1 September 2010

1 reference

Current Neurology and Neuroscience Reports

31 July 2017

1 reference

31 July 2017

10

1 reference

31 July 2017

5

1 reference

31 July 2017

381-388

1 reference

https://scigraph.springernature.com/pub.10.1007/s11910-010-0125-3

31 July 2017

0 references

cites work

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11910-010-0125-3

Birth outcomes in women who have taken leflunomide during pregnancy

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11910-010-0125-3

Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine

21 January 2018

1 reference

12 December 2020

Combination therapy in multiple sclerosis

1 reference

12 December 2020

Compliance, adherence, and the treatment of multiple sclerosis

1 reference

12 December 2020

Statin therapy inhibits remyelination in the central nervous system.

1 reference

12 December 2020

Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes

1 reference

12 December 2020

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

1 reference

12 December 2020

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

1 reference

12 December 2020

Detoxication enzyme inducers modify cytokine production in rat mixed glial cells

1 reference

12 December 2020

Additive effect of the combination of glatiramer acetate and minocycline in a model of MS.

1 reference

12 December 2020

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

12 December 2020

Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis.

1 reference

12 December 2020

Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration

1 reference

12 December 2020

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

12 December 2020

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats

1 reference

12 December 2020

Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial

1 reference

12 December 2020

Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

1 reference

12 December 2020

Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators

1 reference

12 December 2020

Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: Involvement of impaired integrin activation and immunologic synapse formation

1 reference

12 December 2020

Statins as immunomodulators: comparison with interferon-beta 1b in MS.

1 reference

12 December 2020

Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis

1 reference

12 December 2020

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

1 reference

12 December 2020

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

1 reference

12 December 2020

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

12 December 2020

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

12 December 2020

Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology

1 reference

12 December 2020

Metalloproteinases in biology and pathology of the nervous system.

1 reference

12 December 2020

Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide

1 reference

12 December 2020

10.1007/S11910-010-0125-3

Identifiers

DOI

1 reference

PubMed ID

20549393

Dimensions Publication ID

31 July 2017

0 references

1 reference

PubMed ID

20549393